Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease

NCT00025259 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00025259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00025259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2002
Completion date
Not reported
Enrollment
1,734 (actual)
Sites
175

Conditions

As the registry lists them; a condition with its own page is linked.

childhood lymphocyte-depleted classical hodgkin lymphoma, childhood mixed cellularity classical hodgkin lymphoma, childhood nodular lymphocyte predominant hodgkin lymphoma, childhood nodular sclerosis classical hodgkin lymphoma, stage i childhood hodgkin lymphoma, stage ii childhood hodgkin lymphoma, stage iii childhood hodgkin lymphoma, stage iv childhood hodgkin lymphoma